doxazosin and finasteride

doxazosin has been researched along with finasteride in 78 studies

Research

Studies (78)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (5.13)	18.2507
2000's	52 (66.67)	29.6817
2010's	18 (23.08)	24.3611
2020's	4 (5.13)	2.80

Authors

Authors	Studies
Ballard, S; Blagg, J; Fox, D; Kenny, B	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Heinzl, S	1
Frankel, S	1
Chung, M; Hilbert, J; Lawrence, V; Phillips, K; Vashi, V	1
Clifford, GM; Farmer, RD	1
Caprino, L	1
Baldwin, KC; Ginsberg, PC; Harkaway, RC	1
Clementi, G; Costantino, G; Matera, M	1
Baldwin, KC; Ginsberg, PC; Harkaway, RC; Roehrborn, CG	1
Dutkiewics, S	1
Batista-Miranda, JE; Bertrán, PA; Diez, MD; Villavicencio, H	1
Baykara, M; Ciftcioglu, MA; Emreoglu, I; Erdoğru, T; Gulkesen, KH; Koksal, T; Ozbilim, G; Usta, MF	1
Bartsch, G; Boyle, P; Cary, MM; Grossman, EB; Jardin, A; Kirby, RS; Roehrborn, C; Sweeney, M	1
Doherty, AP	1
O'Leary, MP	2
Gonzalez, CM; McVary, KT	1
O'Reilly, P	1
Romics, I	1
Andriole, GL; Bautista, OM; Clarke, HS; Crawford, ED; Diokno, A; Dixon, CM; Foley, JP; Foster, HE; Jacobs, SC; Kaplan, SA; Kreder, KJ; Kusek, JW; Lepor, H; Lieber, MM; Lucia, MS; McConnell, JD; McVary, KT; Menon, M; Milam, DF; Miller, GJ; Nyberg, LM; Ramsdell, JW; Roehrborn, CG; Schenkman, NS; Slawin, KM; Smith, JA	1
Ellis, RJ; Lee, SC	1
Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C	1
Brown, GA; Sussman, DO	1
Bosch, RJ; Sturkenboom, MC; Verhamme, KM	1
Fitzpatrick, JM; Kirby, RS	1
Doggrell, SA	2
Bernard, L; Brisson, M; Hux, M; McDonald, H; Nickel, JC	1
Hausmann, R; Reich, O; Steif, CG; Thalmann, G	1
McNeill, SA; Turner, K	1
Howe, RW; MacDonald, R; Wilt, TJ	1
Biddle, AK; DiSantostefano, RL; Lavelle, JP	1
Kaplan, SA; Kusek, JW; Lee, MW; McConnell, JD; Meehan, AG; Noble, WR; Nyberg, LM; Roehrborn, CG	1
Cheng, TO	1
Bautista, OM; Crawford, ED; Kusek, JW; Lieber, MC; McConnell, JD; Meehan, AG; Noble, WR; Nyberg, LM; Roehrborn, CG; Slawin, KM; Smith, JA; Wilson, SS	1
Bhardwa, J; Goldstraw, M; Kirby, R; Tzortzis, S	1
Jewett, MA; Klotz, LH	1
Burrows, PK; Johnson, TM; Kusek, JW; Lepor, H; Nyberg, LM; Roehrborn, CG; Tenover, JL	1
Kreder, KJ; Lutgendorf, SK; Ullrich, PM	1
Gratzke, C; Reich, O; Schlenker, B; Seitz, M; Stief, CG; Weidlich, P	1
Jin, J; Kong, CZ; Li, NC; Na, YQ; Qiu, SP; Song, YS; Sun, G; Sun, YC; Sun, YH; Wang, XF; Wu, SL; Ye, ZQ	1
MacDonald, R; Wilt, TJ	1
Andersson, KE	1
Kaplan, SA; Kusek, JW; Lee, JY; McConnell, JD; Meehan, AG; Nyberg, LM; Roehrborn, CG; Rotonda, J; Surynawanshi, S	1
Park, DS; Shim, JY	1
Acquaro, C; Carvalho, RF; Felisbino, SL; Justulin, LA; Silva, MD	1
Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA	1
Fornari, A; Rhoden, CR; Rhoden, EL; Ribeiro, EP; Zettler, CG	1
Breau, RH; Dahm, P; Lavallée, LT	1
Fink, HA; Macdonald, R; Rutks, I; Tacklind, J; Wilt, TJ	1
Krome, S	1
Eggers, PW; Fwu, CW; Kaplan, SA; Kirkali, Z; Kusek, JW; Lee, JY	1
Abrahim-Vieira, B; Cabral, LM; De Sousa, VP; Do Carmo, FA; Lopes, M; Padula, C; Pupe, CG; Ribeiro, AJ; Rodrigues, CR; Santi, P; Veiga, F	1
Burrows, PK; Eggers, PW; Fwu, CW; Kirkali, Z; Kusek, JW; McVary, KT	1
Carini, M; Corona, G; Ficarra, V; Gacci, M; Maggi, M; Novara, G; Sebastianelli, A; Serni, S; Shariat, SF; Zattoni, F	1
Kaplan, SA	1
Kaplan, SA; Kusek, JW; Lee, JY; Meehan, AG	1
Ding, J; Duan, L; Qi, J; Qian, X; Xu, D; Zhu, Y	1
Kang, J; Liu, J; Liu, Q; Qi, J; Zhu, Y	1
Dynda, D; Gupta, N; Helo, S; Holland, B; McVary, KT; Rogers, T	1
Arenas-Duque, A; Garcia-Perdomo, HA; Guevara-Cuellar, CA; Parody-Rúa, E	1
Leverson, GE; Macoska, JA; McVary, KT; Ricke, WA; Uchtmann, KS	1
Roehrborn, CG; Rukstalis, DB	1
Bauer, SR; Covinsky, K; Ensrud, KE; Liu, TT; McVary, KT; Newman, JC; Ricke, WA; Suskind, AM; Walter, LC	1
Alfahmy, A; Fernstrum, AJ; Hijaz, AK; Ju, M; Pham, K; Ray, AW; Ray, S; Sheyn, D	1
McClure, JA; Welk, B	1

Reviews

18 review(s) available for doxazosin and finasteride

Article	Year
Pharmacological options in the treatment of benign prostatic hyperplasia. Journal of medicinal chemistry, 1997, Apr-25, Volume: 40, Issue:9 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship	1997
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
[Prostatic adenoma: new drugs, new surgical techniques]. Medizinische Monatsschrift fur Pharmazeuten, 1992, Volume: 15, Issue:12 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androstenes; Azasteroids; Cystoscopes; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatectomy; Prostatic Hyperplasia; Stents	1992
Measures of Proscar, Hytrin, and Cardura side effects. Neurourology and urodynamics, 1997, Volume: 16, Issue:1 Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia	1997
Medical therapy for benign prostatic hyperplasia: a review of the literature. European urology, 2000, Volume: 38, Issue:1 Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin	2000
[Drugs for the treatment of benign prostatic hypertrophy]. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2000, Volume: 52, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Androgen Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Muscle, Smooth; Plant Extracts; Prazosin; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Serenoa; Sulfonamides; Tamsulosin; Urinary Bladder Neck Obstruction; Urodynamics	2000
Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions. PharmacoEconomics, 2001, Volume: 19, Issue:11 Topics: Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Transurethral Resection of Prostate; Treatment Outcome	2001
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Current urology reports, 2003, Volume: 4, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Treatment Outcome	2003
[Pharmacologic treatment of benign prostatic hyperplasia]. Orvosi hetilap, 2003, Sep-14, Volume: 144, Issue:37 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin	2003
After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:9 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Delivery Systems; Drug Therapy, Combination; Erectile Dysfunction; Finasteride; Humans; Male; Prostatic Hyperplasia	2004
Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU international, 2004, Volume: 94, Issue:9 Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Doxazosin; Drug Combinations; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Treatment Outcome; Urinary Retention	2004
Treatment and pharmacologic management of BPH in the context of common comorbidities. The American journal of managed care, 2006, Volume: 12, Issue:5 Suppl Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Comorbidity; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Global Health; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome	2006
Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:9 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2007
[Benign prostatic hyperplasia: medical therapy]. MMW Fortschritte der Medizin, 2007, Aug-16, Volume: 149, Issue:33-34 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Disease Progression; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Muscarinic Antagonists; Phosphodiesterase Inhibitors; Phytotherapy; Plant Extracts; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome	2007
Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clinical interventions in aging, 2006, Volume: 1, Issue:4 Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Combinations; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urinary Tract; Urodynamics	2006
Finasteride for benign prostatic hyperplasia. The Cochrane database of systematic reviews, 2010, Oct-06, Issue:10 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatism; Randomized Controlled Trials as Topic	2010
[How effective is finasteride?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:8 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin	2011
Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. The journal of sexual medicine, 2014, Volume: 11, Issue:6 Topics: Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Doxazosin; Dutasteride; Ejaculation; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Sexual Dysfunction, Physiological; Sulfonamides; Tamsulosin; Urological Agents	2014

Trials

18 trial(s) available for doxazosin and finasteride

Article	Year
Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin. Journal of clinical pharmacology, 1998, Volume: 38, Issue:11 Topics: Adrenergic alpha-Antagonists; Adult; Area Under Curve; Doxazosin; Drug Interactions; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Time Factors	1998
Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urologia internationalis, 2001, Volume: 66, Issue:2 Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction	2001
[Long-term therapy of benign prostatic hyperplasia. Our experience]. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2001, Volume: 53, Issue:1 Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Finasteride; Follow-Up Studies; Humans; Male; Mepartricin; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Time Factors	2001
Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology, 2001, Volume: 58, Issue:2 Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Administration Schedule; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia; Treatment Outcome	2001
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology, 2003, Volume: 61, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Diuresis; Double-Blind Method; Doxazosin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Placebo Effect; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome	2003
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. The New England journal of medicine, 2003, Dec-18, Volume: 349, Issue:25 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progression; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Severity of Illness Index	2003
Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:5 Topics: Clinical Trials as Topic; Doxazosin; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin	2004
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. The Journal of urology, 2006, Volume: 175, Issue:1 Topics: Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Urination Disorders	2006
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. The Journal of urology, 2006, Volume: 175, Issue:4 Topics: Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Placebo Effect; Prostatic Hyperplasia; Treatment Outcome	2006
The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. The Journal of urology, 2007, Volume: 178, Issue:5 Topics: Adrenergic alpha-Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Nocturia; Pilot Projects; Prostatic Hyperplasia; Treatment Outcome; Urodynamics	2007
[Comparison of different drugs on the treatment of benign prostate hyperplasia]. Zhonghua wai ke za zhi [Chinese journal of surgery], 2007, Jul-15, Volume: 45, Issue:14 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; Double-Blind Method; Doxazosin; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Plant Extracts; Prazosin; Prostate; Prostatic Hyperplasia; Quality of Life; Secale; Sulfonamides; Tamsulosin; Treatment Outcome	2007
Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. The Journal of urology, 2008, Volume: 180, Issue:3 Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Time Factors; Ultrasonography	2008
Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. The Journal of urology, 2013, Volume: 190, Issue:1 Topics: Administration, Oral; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Drug Administration Schedule; Drug Therapy, Combination; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Reference Values; Severity of Illness Index; Statistics, Nonparametric; Time; Treatment Outcome	2013
Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. The Journal of urology, 2014, Volume: 191, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Sexuality; Surveys and Questionnaires; Treatment Outcome; Urination	2014
Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial. The Journal of urology, 2016, Volume: 195, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Incidence; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Time Factors	2016
Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial. The Journal of urology, 2018, Volume: 200, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Cystoscopy; Disease Progression; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Hyperthermia, Induced; Male; Middle Aged; Organ Size; Prostate; Prostatic Hyperplasia; Steam; Time Factors; Treatment Outcome	2018
Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study. The Journal of urology, 2019, Volume: 202, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Biopsy; Cohort Studies; Disease Progression; Doxazosin; Drug Therapy, Combination; Fibrosis; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Time Factors; Treatment Outcome	2019
The Reduction of Male Lower Urinary Tract Symptoms Is Associated With a Decreased Risk of Death. The Journal of urology, 2023, Volume: 210, Issue:4 Topics: Doxazosin; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Pelvis; Prostate	2023

Other Studies

42 other study(ies) available for doxazosin and finasteride

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. International urology and nephrology, 2001, Volume: 32, Issue:3 Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Phytotherapy; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin	2001
Two-drug therapy is best for symptomatic prostate enlargement: combination should change clinical practice. Journal of the American College of Surgeons, 2002, Volume: 195, Issue:2 Topics: Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Hyperplasia; Treatment Outcome	2002
Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia. Urologia internationalis, 2002, Volume: 69, Issue:4 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Retrospective Studies	2002
[5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia]. MMW Fortschritte der Medizin, 2002, Oct-31, Volume: 144, Issue:44 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Time Factors	2002
Second opinion. I have benign prostatic hyperplasia. The drug my doctor prescribed has helped somewhat, but I'm still making a lot of trips to the bathroom at night. Short of surgery, are there any new approaches to managing this condition that might be m Mayo Clinic health letter (English ed.), 2002, Volume: 20, Issue:12 Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2002
Benign prostatic hyperplasia. Hospital medicine (London, England : 1998), 2003, Volume: 64, Issue:2 Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quinazolines	2003
By the way, doctor. I'm 77 and have an enlarged prostate. I take Proscar once a day and saw palmetto three times a day. Yet I still have to get up two to seven times a night to urinate. What can I do to reduce the frequency of urination? Harvard health letter, 2003, Volume: 28, Issue:6 Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Urination Disorders	2003
Pharmaceutical review. BJU international, 2003, Volume: 92, Issue:3 Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Risk Assessment; Urinary Retention	2003
[5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked]. MMW Fortschritte der Medizin, 2003, Jul-10, Volume: 145, Issue:27-28 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Age Factors; Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Germany; Humans; Male; Middle Aged; Placebos; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic	2003
[Benign prostatic syndrome. 3-step plan for the treatment]. MMW Fortschritte der Medizin, 2003, Sep-25, Volume: 145, Issue:39 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Placebos; Prognosis; Prostate-Specific Antigen; Prostatic Hyperplasia; Risk Factors; Ultrasonography	2003
[Two drugs have a better outcome. Finasteride plus alpha blocker improves urine flow]. MMW Fortschritte der Medizin, 2003, Nov-20, Volume: 145, Issue:47 Topics: Adrenergic alpha-Antagonists; Aged; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Urodynamics	2003
Male breast cancer during finasteride therapy. Journal of the National Cancer Institute, 2004, Feb-18, Volume: 96, Issue:4 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Breast Neoplasms, Male; Carcinoma, Ductal; Doxazosin; Drug Labeling; Enzyme Inhibitors; Finasteride; Gynecomastia; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; United States	2004
Herbal and vitamin supplement use in a prostate cancer screening population. Urology, 2004, Volume: 63, Issue:2 Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietary Supplements; Doxazosin; Drug Utilization; Family; Finasteride; Health Surveys; Humans; Male; Mass Screening; Middle Aged; Penile Erection; Phytotherapy; Plant Preparations; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Self Medication; Socioeconomic Factors; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Urination Disorders; Vitamins	2004
A current review of medical therapy for benign prostatic hyperplasia. The Journal of the American Osteopathic Association, 2004, Volume: 104, Issue:2 Suppl 2 Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination Disorders	2004
Finasteride in benign prostatic hyperplasia. The New England journal of medicine, 2004, Mar-25, Volume: 350, Issue:13 Topics: 5-alpha Reductase Inhibitors; Acute Disease; Adrenergic alpha-Antagonists; Cohort Studies; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Retrospective Studies; Urinary Retention	2004
Two-drug therapy is best for symptomatic prostate enlargement: could a combination of doxazosin and finasteride change clinical practice? BJU international, 2004, Volume: 93, Issue:7 Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2004
An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. The Canadian journal of urology, 2004, Volume: 11, Issue:4 Topics: Adrenergic alpha-Antagonists; Cost-Benefit Analysis; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Models, Economic; Prostatic Hyperplasia	2004
[Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination]. Aktuelle Urologie, 2004, Volume: 35, Issue:5 Topics: Adrenergic alpha-Antagonists; Controlled Clinical Trials as Topic; Disease Progression; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Placebos; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors	2004
MTOPS: conclusions about invasive therapy for BPH should be interpreted with caution. BJU international, 2004, Volume: 94, Issue:7 Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia	2004
Finasteride with doxazosin to reduce BPH progression. The Nurse practitioner, 2005, Volume: 30, Issue:3 Topics: Disease Progression; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia	2005
Re: an economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. The Canadian journal of urology, 2005, Volume: 12, Issue:1 Topics: Adrenergic alpha-Antagonists; Cost-Benefit Analysis; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quality-Adjusted Life Years	2005
Should patients with benign prostatic hypertrophy stop taking doxazosin in the light of the ALLHAT study? International journal of cardiology, 2006, Feb-15, Volume: 107, Issue:2 Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Antihypertensive Agents; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Glucose Intolerance; Humans; Hyperlipidemias; Hypertension; Male; Myocardial Infarction; Prostatic Hyperplasia	2006
Benign prostatic hyperplasia (BPH). Harvard men's health watch, 2006, Volume: 11, Issue:1 Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2006
Advances in the medical management of benign prostatic hyperplasia. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Jun-19, Volume: 176, Issue:13 Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2007
Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperplasia. Urology, 2007, Volume: 70, Issue:3 Topics: Aged; Blood Pressure; Doxazosin; Finasteride; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Organ Size; Pituitary-Adrenal System; Prostate; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Saliva; Stress, Psychological; Sympathetic Nervous System; Testosterone; Ultrasonography; Urinary Bladder; Urination Disorders	2007
How many drugs for LUTS due to BPH are too many? The Journal of urology, 2008, Volume: 180, Issue:3 Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Humans; Imidazoles; Male; Muscarinic Antagonists; Phenylpropanolamine; Piperazines; Prostatic Hyperplasia; Sulfonamides; Sulfones; Tamsulosin; Tolterodine Tartrate; Triazines; Urination Disorders; Vardenafil Dihydrochloride	2008
Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation. Urologia internationalis, 2008, Volume: 81, Issue:4 Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antihypertensive Agents; CD3 Complex; Cyclooxygenase 2; Doxazosin; Enzyme Inhibitors; Finasteride; Glutathione Transferase; Humans; Immunohistochemistry; Inflammation; Male; Middle Aged; Prostatic Hyperplasia; Prostatitis; Vascular Endothelial Growth Factor A	2008
Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology. International journal of andrology, 2010, Jun-01, Volume: 33, Issue:3 Topics: Androgens; Animals; Cell Proliferation; Dihydrotestosterone; Doxazosin; Epithelial Cells; Extracellular Matrix; Finasteride; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Rats; Rats, Wistar; RNA, Messenger; Testosterone; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transforming Growth Factor beta1	2010
When you just can't go: my patient, a 63-year old stockbroker, recalled his experience with acute urinary retention. Consumer reports, 2009, Volume: 74, Issue:8 Topics: Acute Disease; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Urinary Retention	2009
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. The Journal of urology, 2010, Volume: 183, Issue:5 Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Reductase; Chromatography, High Pressure Liquid; Doxazosin; Drug Contamination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tablets; Tamsulosin	2010
Effects of the chronic use of finasteride and doxazosin mesylate on the histomorphometric characteristics of the prostate: experimental study in rats. International urology and nephrology, 2011, Volume: 43, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Doxazosin; Drug Administration Schedule; Drug Therapy, Combination; Finasteride; Follow-Up Studies; Male; Prostate; Prostatic Hyperplasia; Rats; Rats, Wistar; Time Factors; Treatment Outcome	2011
Evidence-based urology in practice: composite endpoints. BJU international, 2010, Volume: 106, Issue:5 Topics: 5-alpha Reductase Inhibitors; Doxazosin; Drug Therapy, Combination; Endpoint Determination; Evidence-Based Medicine; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatism; Risk Reduction Behavior; Treatment Outcome	2010
Development of a doxazosin and finasteride transdermal system for combination therapy of benign prostatic hyperplasia. Journal of pharmaceutical sciences, 2013, Volume: 102, Issue:11 Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Adrenergic alpha-1 Receptor Antagonists; Animals; Azepines; Doxazosin; Finasteride; Humans; Lauric Acids; Male; Permeability; Pharmaceutical Vehicles; Prostatic Hyperplasia; Skin Absorption; Swine	2013
Re: Development of a doxazosin and finasteride transdermal system for combination therapy of benign prostatic hyperplasia. The Journal of urology, 2015, Volume: 193, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Animals; Doxazosin; Finasteride; Humans; Male; Pharmaceutical Vehicles	2015
The new insight of prostate-specific antigen reduction during finasteride therapy in aging men. Aging clinical and experimental research, 2016, Volume: 28, Issue:6 Topics: Aged; Asian People; Doxazosin; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	2016
Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH). International urology and nephrology, 2017, Volume: 49, Issue:3 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatism; Treatment Failure; Ultrasonography; Urinary Bladder; Urological Agents	2017
Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience. Value in health regional issues, 2018, Volume: 17 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adult; Colombia; Cost-Benefit Analysis; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia	2018
Prostatic Urethral Lift Versus Medical Therapy: Examining the Impact on Sexual Function in Men with Benign Prostatic Hyperplasia. European urology focus, 2022, Volume: 8, Issue:1 Topics: Doxazosin; Erectile Dysfunction; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia	2022
Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. JAMA network open, 2021, 11-01, Volume: 4, Issue:11 Topics: Aged; Aged, 80 and over; Disease Progression; Doxazosin; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Finasteride; Follow-Up Studies; Frail Elderly; Frailty; Geriatric Assessment; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Proportional Hazards Models; Prostatic Hyperplasia; Severity of Illness Index; Urological Agents	2021
Development of a machine learning-based predictive model for prediction of success or failure of medical management for benign prostatic hyperplasia. Neurourology and urodynamics, 2023, Volume: 42, Issue:4 Topics: 5-alpha Reductase Inhibitors; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Machine Learning; Male; Prostatic Hyperplasia	2023